Literature DB >> 23228633

Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis.

Li Jia1, David J Waxman.   

Abstract

The anti-tumor activity, metronomic chemotherapy sensitization potential and metastatic effects of the endogenous angiogenesis inhibitors thrombospondin-1 and PEDF were investigated in KM12 colon adenocarcinoma xenografts. Thrombospondin-1 and PEDF decreased KM12 tumor microvessel density, increased macrophage infiltration, and improved responsiveness to metronomic cyclophosphamide (CPA) treatment, but did not activate the anti-tumor innate immunity that metronomic CPA induces in other tumor models. Moreover, thrombospondin-1, but not PEDF, significantly increased KM12 metastasis to the lung, while PEDF augmented the anti-metastatic activity of metronomic CPA. Thus, while thrombospondin-1 and PEDF both increase the KM12 tumor responsiveness to metronomic CPA, they have disparate effects on tumor metastasis.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23228633      PMCID: PMC3563872          DOI: 10.1016/j.canlet.2012.11.055

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  55 in total

1.  Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47.

Authors:  Sukhbir Kaur; Gema Martin-Manso; Michael L Pendrak; Susan H Garfield; Jeff S Isenberg; David D Roberts
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

Review 2.  Metronomic chemotherapy: new rationale for new directions.

Authors:  Eddy Pasquier; Maria Kavallaris; Nicolas André
Journal:  Nat Rev Clin Oncol       Date:  2010-06-08       Impact factor: 66.675

3.  Growth suppression of cervical carcinoma by pigment epithelium-derived factor via anti-angiogenesis.

Authors:  Jun Yang; Shuqin Chen; Xuan Huang; Jiande Han; Qingsong Wang; Dingbo Shi; Rui Cheng; Guoquan Gao; Xia Yang
Journal:  Cancer Biol Ther       Date:  2010-06-08       Impact factor: 4.742

Review 4.  Metronomic chemotherapy: Back to the future!

Authors:  Nicolas André; Laetitia Padovani; Arnauld Verschuur
Journal:  Drug News Perspect       Date:  2010-03

5.  Pigment epithelium-derived factor stimulates tumor macrophage recruitment and is downregulated by the prostate tumor microenvironment.

Authors:  Sofia Halin; Stina Häggström Rudolfsson; Jennifer A Doll; Susan E Crawford; Pernilla Wikström; Anders Bergh
Journal:  Neoplasia       Date:  2010-04       Impact factor: 5.715

6.  A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma.

Authors:  Louis B Nabors; John B Fiveash; James M Markert; Manasi S Kekan; George Y Gillespie; Zhi Huang; Martin J Johnson; Sreelatha Meleth; Huichien Kuo; Candece L Gladson; Hassan M Fathallah-Shaykh
Journal:  Arch Neurol       Date:  2010-03

Review 7.  Pigment epithelium-derived factor as an impending therapeutic agent against vascular epithelial growth factor-driven tumor-angiogenesis.

Authors:  Katrina B Manalo; Peter F M Choong; Crispin R Dass
Journal:  Mol Carcinog       Date:  2010-12-10       Impact factor: 4.784

8.  The immune response and the therapeutic effect of metronomic chemotherapy with cyclophosphamide.

Authors:  Viviana R Rozados; Leandro E Mainetti; María J Rico; Mariano F Zacarías Fluck; Pablo Matar; O Graciela Scharovsky
Journal:  Oncol Res       Date:  2010       Impact factor: 5.574

9.  B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.

Authors:  Carmelo Nucera; Alessandro Porrello; Zeus Andrea Antonello; Michal Mekel; Matthew A Nehs; Thomas J Giordano; Damien Gerald; Laura E Benjamin; Carmen Priolo; Efisio Puxeddu; Stephen Finn; Barbara Jarzab; Richard A Hodin; Alfredo Pontecorvi; Vânia Nose; Jack Lawler; Sareh Parangi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-24       Impact factor: 11.205

10.  PEDF inhibits VEGF- and EPO- induced angiogenesis in retinal endothelial cells through interruption of PI3K/Akt phosphorylation.

Authors:  Banumathi Elayappan; Haribalaganesh Ravinarayannan; Sheik Pran Babu Sardar Pasha; Kyung-jin Lee; Sangiliyandi Gurunathan
Journal:  Angiogenesis       Date:  2009       Impact factor: 9.596

View more
  11 in total

1.  Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy.

Authors:  Annabelle Chow; Amy Wong; Giulio Francia; Shan Man; Robert S Kerbel; Urban Emmenegger
Journal:  Invest New Drugs       Date:  2013-06-02       Impact factor: 3.850

Review 2.  Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect.

Authors:  Guido Bocci; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2016-05-17       Impact factor: 66.675

3.  Tumor dynamics in response to antiangiogenic therapy with oral metronomic topotecan and pazopanib in neuroblastoma xenografts.

Authors:  Sushil Kumar; Reza Bayat Mokhtari; Indhira Dias Oliveira; Syed Islam; Silvia Regina Caminada Toledo; Herman Yeger; Sylvain Baruchel
Journal:  Transl Oncol       Date:  2013-08-01       Impact factor: 4.243

Review 4.  Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance.

Authors:  Irina Kareva; David J Waxman; Giannoula Lakka Klement
Journal:  Cancer Lett       Date:  2014-12-23       Impact factor: 8.679

5.  Center of cancer systems biology second annual workshop--tumor metronomics: timing and dose level dynamics.

Authors:  Philip Hahnfeldt; Lynn Hlatky; Giannoula Lakka Klement
Journal:  Cancer Res       Date:  2013-03-14       Impact factor: 12.701

Review 6.  Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy.

Authors:  Junjie Wu; David J Waxman
Journal:  Cancer Lett       Date:  2018-04-10       Impact factor: 8.679

7.  Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8+ T-cell responses and immune memory.

Authors:  Junjie Wu; David J Waxman
Journal:  Oncoimmunology       Date:  2015-02-18       Impact factor: 8.110

8.  Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts.

Authors:  Joshua C Doloff; David J Waxman
Journal:  BMC Cancer       Date:  2015-05-08       Impact factor: 4.430

Review 9.  T-cell modulation by cyclophosphamide for tumour therapy.

Authors:  Ellyn Hughes; Martin Scurr; Emma Campbell; Emma Jones; Andrew Godkin; Awen Gallimore
Journal:  Immunology       Date:  2018-03-09       Impact factor: 7.397

10.  Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.

Authors:  T Nelius; D Martinez-Marin; J Hirsch; B Miller; K Rinard; J Lopez; W de Riese; S Filleur
Journal:  Cell Death Dis       Date:  2014-05-08       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.